secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2023-04-10T23:59:59+00:00
Accession:  0001104659-23-043287
Event type: other_material
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron expects $56M IPR&D charge in Q1 2023 from Sonoma collaboration, ~$0.42 EPS impact
--------------------------------------------------------------------------------

- Pre-tax acquired IPR&D charge of ~$56M for Q1 2023 related to Sonoma Biotherapeutics collaboration.
- Expected to reduce both GAAP and non-GAAP diluted EPS by approximately $0.42.
- Charge is preliminary and subject to final financial statement closing procedures.
- Relates to an up-front payment under the previously announced collaboration and license agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000110465923043287/0001104659-23-043287-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000110465923043287/tm2312136d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-043287

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer